NCT06514794: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Wugen, Inc.. Phase: PHASE2. Conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma